COVID-19 increases chronic fatigue risk

Study reveals that COVID-19 significantly increases the risk of chronic fatigue syndrome, with specific populations, such as older adults, Asians, and non-hospitalized patients, at higher risk.

StromaForte by Swedish StromaBio for Cardiovascular Disease: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

November 6, 2023

Poxel takes writedown on NASH drug as it continues layoffs, search for cash

France’s Poxel still believes that it can blaze a path forward in rare diseases — but before it can convince investors or partners of that,

September 27, 2023

Health experts redefine cardiovascular disease risk, prevention and management

Health experts are redefining cardiovascular disease (CVD) risk, prevention and management, according to a new American Heart Association presidential advisory published today in the Association’s

October 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.